IP Library › Granted Patent US 7,202,042
Granted Patent B2
US 7,202,042 · App. 10/697,356 · Granted Apr 10, 2007

Rapid evaluation of the ratio of biological molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,202,042
App. No.
10/697,356
Filed
Oct 29, 2003
Granted
Apr 10, 2007
Kind
B2
Art Unit
1678
USPC
435/7.1
Abstract

The invention relates in part to novel methods of rapidly determining the ratio of biological molecules. The invention also relates in part to a kit for rapidly determining the ratio of biological molecules.

Claims (15)

1. A method for determining the ratio of oxidized cardiac troponin I to reduced cardiac troponin I in a patient sample, comprising:

a) contacting the patient sample with

i) a first antibody that specifically binds to both oxidized and reduced cardiac troponin I, wherein said oxidized and reduced cardiac troponin I bind to the first antibody in an amount proportional to their ratio in the sample, and

ii) a second antibody that specifically binds to one of oxidized or reduced cardiac troponin I, whereby said first and second antibodies form a complex comprising one of said oxidized or reduced cardiac troponin I present in said sample, and wherein if said second antibody forms a complex comprising oxidized troponin I, said second antibody does not form a complex comprising reduced troponin I and wherein if said second antibody forms a complex comprising reduced troponin I, said second antibody does not form a complex comprising oxidized troponin I; and

b) generating a signal corresponding to the amount of said complex formed and relating said signal to said ratio.

2. A method according to claim 1 , wherein one of said first or second antibodies is attached to a signal generating element, and the other of said first or second antibodies is attached to a solid phase.

3. A method according to claim 2 , wherein said signal generating element comprises an enzyme, a colloidal metal particle, a latex particle, or a silica particle.

4. A method according to claim 1 , wherein said signal is detected by fluorometric measurement.

5. A method according to claim 1 , wherein said signal is detected by absorbance measurement.

6. A method according to claim 1 , wherein said signal is detected by pH measurement.

7. A method according to claim 1 , wherein said signal is generated from a separate component that specifically binds to said complex and that is attached to a signal generating element.

8. A method according to claim 1 , wherein said relating step comprises comparing said signal to a standard curve calculated using known ratios of oxidized and reduced cardiac troponin I.

9. A method according to claim 1 , wherein said relating step comprises the use of a normalizing factor calculated using known ratios of oxidized and reduced cardiac troponin I.

10. A method according to claim 1 , wherein said patient sample is contacted with said first and second antibodies simultaneously in the same vessel.

11. A method according to claim 1 , wherein said ratio is further related to the occurrence of a myocardial infarction in said patient.

Assignments (2)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →